Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0030193 (
pain
)
261,466
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Dorsal column stimulators (DCS) have been implanted in 130 patients with various chronic pain syndromes at the University of California, San Francisco, between 1969 and 1973. Preoperative psychiatric evaluation and percutaneous dorsal column stimulation testing were of value in rejecting those patients most likely to have unsatisfactory long-term results with DCS. Best results occurred in patients with phantom limb or peripheral
nerve pain
and worst results in patients with paraplegic
pain
, documented arachnoiditis, pancreatitis and arthritis. The need is stressed for careful preoperative selection and for close, prolonged postoperative care in a situation permitting access to multidisciplinary facilities for patient care.
...
PMID:Experience with dorsal column stimulation for relief of chronic intractable pain: 1968-1973. 108 Aug 99
For a patient suffering with his legs, the
pain
is usually associated with the presence of one or more varices that can be seen. The physician must not fall into this trap. Questioning is vital. Establishing the kind of
pain
and the conditions under which it occurs may elok for (1) a rheumatological etioloty: sciatic or crural
nerve pain
, calcaneal
pain
: (2) a surgical etiology: an inguinal or particularly a crural hernia, a popliteal cyst; (3) a medical etiology: exogenous polyneuritis, hypokalaemia resulting from the abuse of laxatives or of diuretics, etc.
...
PMID:[Pitfalls during phlebology consultation]. 108 1
Exposure to sauna heat during sauna bathing raises the skin temperature of the bather near the hot
pain
perception threshold and enhances sympathetic activity. Self-reports provided by regular bathers of changes in intensity of their ongoing
pain
might, therefore, add novel information on the effect of intense heat on various
pain
conditions. We interviewed consecutive patients attending our
pain
clinic over a period of 1 year about their
pain
-related responses to sauna bathing and controlled the results by quantitated somatosensory tests. There were 61 patients with chronic neuropathic
pain
of peripheral origin, 13 patients with central
pain
and 59 patients with rheumatoid
pain
. Allodynia and hyperalgesia to heat were relatively infrequent in all groups (10%, 15% and 8%, respectively). Three out of 17 patients with postinjury
nerve pain
reported similar exacerbation. By contrast, mechanical allodynia was present in 48% of patients with peripheral neuropathic
pain
and in 54% of patients with central
pain
. The results speak against an important role for C-afferent or sympathetic postganglionic fibres in most subclasses of neuropathic
pain
. Animal models of neuropathic
pain
should be critically viewed against this finding.
Pain
1992 Apr
PMID:Effect of exposure to sauna heat on neuropathic and rheumatoid pain. 137 27
Morton's neuroma is one of the most common causes of
nerve pain
in the foot. This article describes the treatment of this condition with carbon dioxide laser surgery, presenting the disadvantages and advantages of this method. This method has proven to be effective; postoperative
pain
and healing time are decreased and patients are able to resume normal ambulation faster than with conventional scalpel surgery.
...
PMID:Treatment of Morton's neuroma with the carbon dioxide laser. 139 87
In a series of 25 patients with head and neck cancer who had severe
pain
, the type and cause of the
pain
were analyzed. There were two types of
pain
: nociceptive and non-nociceptive. Nineteen (76%) patients had nociceptive
pain
that could be subdivided into actual nociceptive
pain
(9 patients), nociceptive
nerve pain
(8 patients), or referred
pain
(2 patients). The cause of nociceptive
pain
was secondary to tumor recurrence in 16 patients and secondary to benign inflammation in 3 patients. Of the six (23%) cases of non-nociceptive
pain
, all were diagnosed as neuropathic
pain
secondary to the sequels of neck dissection. World Health Organization guidelines were applied for the treatment of symptomatic
pain
of nociceptive
pain
; if necessary, nerve blocks were used after this treatment. Non-nociceptive
pain
was usually treated with amitriptyline or carbamazepine. If tumor recurrence was the cause of the
pain
, antitumor-directed therapy was applied, when possible. Relief was achieved in 52% of the patients after two attempts to treat
pain
, in 64% after three attempts, and in up to 72% after four attempts.
Pain
could not be controlled in 28% of the patients. Patients with tumor recurrence had a short median survival time of 3 months, regardless of
pain
control. Patients with neuropathic
pain
had a survival time of 16 months or more (median not reached). The authors conclude that the type and cause of the
pain
in cancer of the head and neck can be determined; this can lead to the administration of proper symptomatic therapy or treatment directed at the underlying cause. In most cases, several successive attempts to treat
pain
were made before relief was achieved.
...
PMID:Types and causes of pain in cancer of the head and neck. 160 40
Our experience in treating 10 patients with intractable
pain
with paraplegia employing percutaneous epidural or dorsal column stimulation is presented. Initial and long-term results in this group are contrasted with those of 9 patients with intractable post-amputation or post-traumatic neuroma
pain
. The successful results of neurostimulation treatment of peripheral
nerve pain
contasts with the disappointing results in the treatment of paraplegic
pain
.
Pain
1980 Feb
PMID:Neurostimulation in the modulation of intractable paraplegic and traumatic neuroma pains. 696 47
This paper presents epidemiological data on silent nerve function impairment in leprosy based on a retrospective study of 536 patients registered at Green Pastures Hospital, Pokhara, West Nepal. Because of the multiple possible aetiologies it is proposed that the clinical phenomenon should be named 'Silent Neuropathy' (SN). We defined this as sensory or motor impairment without skin signs of reversal reaction or erythema nodosum leprosum (ENL), without evident nerve tenderness and without spontaneous complaints of
nerve pain
(burning or shooting
pain
), paraesthesia or numbness. The functioning of the main peripheral nerve trunks known to be affected in leprosy was assessed using a nylon filament to test touch thresholds and a manual voluntary muscle test to quantify muscle strength. Almost 7% of new patients had SN at first examination. The incidence rate of SN among the 336 new patients who were available for follow-up was 4.1 per 100 person years at risk. In total, 75% of all SN episodes diagnosed after the start of chemotherapy occurred during the first year of treatment. During steroid treatment the sensory and motor function in nerves affected by SN improved significantly (p = 0.012, Wilcoxon matched-pairs signed ranks test) over a period of 3 months. The patients with more extensive clinical disease (3/9 or more body areas involved, more than 3 enlarged nerves or a positive skin smear) were found to be at increased risk of developing SN. We discuss 4 different possible aetiologies of SN: 1, Schwann cell pathology; 2, nerve fibrosis; 3, cell-mediated immune reaction; and 4, intra-neural ENL. Some epidemiological evidence is presented that suggests that SN cannot be equated with a 'reversal reaction expressing itself in the nerves'. It is recommended that all patients should have a nerve function assessment at every visit to the clinic at least during their first year of treatment. Regular nerve function assessment is essential to detect SN at an early stage and to prevent permanent impairment of nerve function.
...
PMID:Silent neuropathy in leprosy: an epidemiological description. 888 21
Chronic somatic peripheral
nerve pain
was treated prospectively in 24 nonrandomized patients by a program of direct electrical nerve stimulation. Patients qualified for the program if anesthetic (lidocaine) nerve block of the involved cutaneous zone of the peripheral nerve relieved symptoms and transcutaneous electrical nerve stimulation transiently improved and did not exacerbate somatic
pain
. Results were judged according to a
pain
score. Patients noted improved sleep and complete absence of the need for narcotic
pain
medication. On the basis of subjective and objective criteria, 18 patients had good or excellent results and 6 had implant failures. Of the six patients with failures, three failed the trial period and did not have implantation, and three had no significant
pain
relief and were judged as treatment failures. Three patients had late equipment failure after initial good results. Most patients had some relief of
pain
, which increased their quality of life and eliminated the need for narcotic analgesia. Direct electrical nerve stimulation should be considered for somatic peripheral
nerve pain
that has not been ameliorated with other methods. It will reduce, although not necessarily eliminate,
pain
and
pain
behavior in most patients.
...
PMID:Chronic peripheral nerve pain treated with direct electrical nerve stimulation. 787 91
It is uncertain whether there exists a nociceptive component in malignant
nerve pain
responsive to NSAIDs and opioids. 20 patients with malignant
nerve pain
were randomly assigned to treatment with naproxen 1500 mg versus slow-release morphine 60 mg daily during 1 week, followed by cross-over medication during the second week in a double-blind, double-dummy protocol. In the 16 evaluable patients, a significant (P < 0.05) reduction of 26% (S.E. +/- 7.9) in
pain
intensity was reached at day 7, compared to baseline
pain
. At day 7, significant
pain
relief of 32% (P < 0.05) was observed in the naproxen group, but not in the morphine group (21%, P = 0.14). Patients using morphine needed approximately twice as much paracetamol rescue than patients using naproxen. Additional
pain
relief could be observed in 4/9 patients with cross-over medication. These data support the concept of a nociceptive component in malignant
nerve pain
responding to NSAIDs and opioids, and favour the combination of both an anti-inflammatory drug and an opioid for symptomatic
pain
relief.
...
PMID:Medical therapy of malignant nerve pain. A randomised double-blind explanatory trial with naproxen versus slow-release morphine. 799 6
This study aimed to identify areas of disagreement in the management of neurogenic
pain
. A short questionnaire was mailed to 179 consultants with an interest in chronic pain (response rate 89%). The questionnaire listed 11 specific conditions involving
nerve pain
(e.g., post-herpetic neuralgia, causalgia) together with 11 treatments (e.g., antidepressants, neurectomy). Consultants were asked to rate the use of each treatment for each condition as 'appropriate', 'no value or positively harmful' or 'no opinion'. Much disagreement emerged about the value of each therapy for each condition: in almost every instance at least some consultants disagreed with the majority view. The dissenting minority was greater than 20% of those who gave an opinion for 48 of the 121 applications of therapy asked about. The appropriateness of treatments for trigeminal neuralgia, amputation stump pain and phantom
pain
was most often in dispute and there was little consensus on the value of nerve blocks. There were a few areas of near agreement. Antidepressants and anticonvulsants were mostly identified as appropriate for all the conditions listed and there was some agreement that strong opioids and the neuroablative techniques were appropriate for cancer pressure or infiltration of nerves but, with a few exceptions, of no value for all other neurogenic
pain
conditions. Divergence of views about treatments may indicate a lack of credible evidence on the value of therapies or a lack of professional knowledge. Where published evidence is clear, the consequences for patients may be under-use of useful therapies or potential iatrogenic harm.
Pain
1993 Sep
PMID:Polarised views on treating neurogenic pain. 823 50
1
2
3
4
5
6
Next >>